Skip to content

Drug interactions

Natalizumab + Ocrelizumab

Severity: Major

Natalizumab and Ocrelizumab: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Ocrelizumab depletes B cells and natalizumab restricts lymphocyte trafficking. Used together or in close sequence, they can increase infection risk, including PML.

What this interaction means in plain words

Natalizumab and Ocrelizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Natalizumab belongs to Gastrointestinal Tract; Ocrelizumab belongs to Central Nervous System.

Evidence level: Low

Why it happens

Additive immunosuppression via B-cell depletion and integrin-mediated lymphocyte trafficking blockade.

What to do

Avoid concurrent use. When switching, follow PML risk assessment including baseline MRI and monitor for infection.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Natalizumab and Ocrelizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Natalizumab with Ocrelizumab?

MediHelp rates the interaction as major. Natalizumab and Ocrelizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Ocrelizumab depletes B cells and natalizumab restricts lymphocyte trafficking. Used together or in close sequence, they can increase infection risk, including PML.

How serious is the interaction between Natalizumab and Ocrelizumab?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use. When switching, follow PML risk assessment including baseline MRI and monitor for infection.

What other medicines interact with Natalizumab?

MediHelp also lists interactions of Natalizumab with, for example, Vedolizumab, Axicabtagene ciloleucel, Baricitinib. The full list is on the Natalizumab page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in